Overview

Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors

Status:
Recruiting
Trial end date:
2023-01-20
Target enrollment:
Participant gender:
Summary
1. Screening stage 2. Evaluation of disease 3. Grouping of patients 4. Infusion of cells 5. Surveillance of adverse effect
Phase:
Phase 3
Details
Lead Sponsor:
Li Yu
Treatments:
Decitabine